Page 2 - Dyne Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dyne therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dyne Therapeutic Today - Breaking & Trending Today

Dyne Therapeutics' Duchenne muscular dystrophy treatment shows promise

Dyne released promising new data on its Duchenne muscular dystrophy drug, DYNE-251, as well as its myotonic dystrophy type 1 treatment DYNE-101. ....

Wildon Farwell , Joshua Brumm , Dyne Therapeutic , Sarepta Therapeutic , Drug Administration ,

Reviewing Dyne Therapeutics (NASDAQ:DYN) & Capstone Therapeutics (OTCMKTS:CAPS)

Capstone Therapeutics (OTCMKTS:CAPS – Get Rating) and Dyne Therapeutics (NASDAQ:DYN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability. Risk and Volatility Capstone Therapeutics has a beta of […] ....

United States , Capstone Therapeutics Corp , Dyne Therapeutics Inc , Capstone Therapeutics , Get Rating , Dyne Therapeutics , Given Dyne Therapeutic , Dyne Therapeutic , Capstone Therapeutics Daily , Otcmkts Caps , Stock Comparison , Stock Analysis ,

FDA Grants Fast Track Designation to Dyne's Treatment for Duchenne Muscular Dystrophy

FDA Grants Fast Track Designation to Dyne's Treatment for Duchenne Muscular Dystrophy
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United States , Wildon Farwell , Drug Administration , Fast Track , Dyne Therapeutic , Accelerated Approval , Priority Review ,

Analysts Anticipate Dyne Therapeutics, Inc. (NYSE:DYN) to Announce -$0.81 Earnings Per Share

Brokerages expect Dyne Therapeutics, Inc. (NYSE:DYN – Get Rating) to report earnings per share (EPS) of ($0.81) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Dyne Therapeutics’ earnings, with estimates ranging from ($0.88) to ($0.70). Dyne Therapeutics posted earnings per share of ($0.58) during the same quarter last year, which […] ....

United States , Zacks Investment Research , Dyne Therapeutics Inc , Dyne Therapeutics Company Profile Get Rating , Dyne Therapeutics , Get Rating , Dyne Therapeutic , Therapeutics Company Profile , Nyse Dyn ,

-$0.88 Earnings Per Share Expected for Dyne Therapeutics, Inc. (NYSE:DYN) This Quarter

Brokerages expect Dyne Therapeutics, Inc. (NYSE:DYN – Get Rating) to post earnings per share (EPS) of ($0.88) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Dyne Therapeutics’ earnings. The lowest EPS estimate is ($1.06) and the highest is ($0.74). Dyne Therapeutics reported earnings per share of ($0.50) during […] ....

United States , Zacks Investment Research , Dyne Therapeutics Inc , Dyne Therapeutics , Get Rating , Dyne Therapeutic , Nyse Dyn ,